Anzeige
Mehr »
Login
Freitag, 24.01.2025 Börsentäglich über 12.000 News von 683 internationalen Medien
Hinter dem nuklearen Ansturm im Silicon Valley: Eine strategische Chance entsteht
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 893072 | ISIN: TRASISEW91Q3 | Ticker-Symbol:
Branche
Chemie
Aktienmarkt
Sonstige
1-Jahres-Chart
TURKIYE SISE VE CAM FABRIKALARI AS Chart 1 Jahr
5-Tage-Chart
TURKIYE SISE VE CAM FABRIKALARI AS 5-Tage-Chart
GlobeNewswire (Europe)
152 Leser
Artikel bewerten:
(0)

Türkiye Sise ve Cam Fabrikalari: Sisecam's net sales reached TRY 41 billion in the first 3 months of the year

Finanznachrichten News

ISTANBUL, June 03, 2024 (GLOBE NEWSWIRE) -- Sisecam is actively pursuing global growth with production operations spanning 14 countries on four continents and sales in over 150 countries. In the first 3 months of 2024, Sisecam recorded consolidated net sales of TRY 41 billion (USD 1.3 billion). In the first 3 months of the year, international sales accounted for 61% of Sisecam's total sales. Sisecam reported total investments of TRY 4.3 billion (USD 136 million) and exports of USD 262 million in the same period.

Sisecam announced financial results for the first 3 months of 2024. In the three-month period, Sisecam's consolidated net sales totaled TRY 41 billion (USD 1.3 billion). International sales - comprising the total of exports made from Türkiye and sales from foreign production - accounted for 61% of consolidated sales. Sisecam's total investments in the same period amounted to TRY 4.3 billion (USD 136 million) while exports totaled USD 262 million. Sisecam produced 1.3 million tons of glass, 1.2 million tons of soda ash, and 0.87 million tons of industrial raw materials in the same period.

USD 114 million investment in three coated glass lines

In 2024, Sisecam entered the year with a decision to invest in three new coated glass lines with a total capacity of nearly 20 million square meters in Türkiye, Italy, and Bulgaria. The company aims to meet the increasing demand for coated glass in the flat glass sector with this investment project, including the ongoing construction of a flat glass facility in Tarsus, Türkiye, as well as flat glass facilities in Northern Italy and Bulgaria. Sisecam also aims to maintain its competitiveness by improving operational efficiency, expanding its production range and increasing the share of value-added products in production volume to create added value for all stakeholders. With an investment of $114 million, the new coated lines will bring Sisecam's total number of glass coating lines worldwide to seven. As a result of these investments, the coated glass capacity will almost double to approximately 42 million square meters.

Eskisehir has become the world's largest glass production hub

Sisecam ignited its new glass packaging furnace in Eskisehir and put its glassware furnace into operation after cold repair in the first 3 months. The additional capacity attained following the ignition of glassware furnace has propelled Sisecam to global leadership in glassware production. As a result of the new investment, Sisecam Eskisehir Glass Packaging Facility has become the world's largest integrated glass packaging production facility with 5 furnaces and 24 lines all on a single site. Thanks to these investments, Sisecam's production facility in Eskisehir has become the largest integrated glass production point in the world in the glass packaging and glassware industries.

Sisecam has initiated actions for the second flat glass line investment in its Egyptian joint venture, Saint Gobain Egypt SAE. To facilitate this investment, Sisecam has completed the establishment procedures for a new company. Additionally, Sisecam announced its decision to invest in 175,000 tons per year incremental capacity in its Mersin soda ash facility. This investment, including working capital, is estimated to cost approximately $125.3 million, with the goal of commissioning it within 2026.

Largest Corporate Bond Issuance in Turkish Republic's History

The global confidence in Sisecam was reaffirmed by the demand for its Eurobond issuance. Sisecam has issued a total of $1.1 billion in Eurobonds, consisting of $500 million with a 5-year term and $600 million with an 8-year term, to international funds and financial institutions. These Eurobond issues received demand exceeding $3.5 billion. This marked the highest demand for the largest corporate bond issue in the history of the Republic of Turkey.

Sisecam tapped the market considering strong demand from institutional investors and increased its Eurobond issuance to $1.5 billion. This issuance attracted nearly $5 billion in demand overall from international institutions. With this additional issuance, Sisecam renewed its record.

Credit Rating Upgrades by Fitch and Moody's

Leading credit rating agencies Fitch and Moody's have upgraded Sisecam by one notch with ratings to above that on the sovereign. Moody's raised Sisecam's credit rating from "B3" to "B2" and maintained the "positive" outlook, while Fitch upgraded Sisecam's long-term foreign currency rating from "B+" to "BB-" and maintained the "positive" outlook.

A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/479ba7fb-e7b4-4446-9e01-6c7437e45157


Sisecam Headquarters.png

© 2024 GlobeNewswire (Europe)
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.